IRIS
MERLOTTI, DANIELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.928
EU - Europa 2.912
AS - Asia 541
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 2
OC - Oceania 2
Totale 7.401
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.921
IE - Irlanda 740
GB - Regno Unito 702
CN - Cina 442
UA - Ucraina 380
SE - Svezia 322
IT - Italia 208
FR - Francia 206
DE - Germania 175
FI - Finlandia 108
VN - Vietnam 41
TR - Turchia 24
ES - Italia 23
BE - Belgio 15
RU - Federazione Russa 10
IN - India 7
CA - Canada 6
EU - Europa 6
IR - Iran 6
DK - Danimarca 4
SY - Repubblica araba siriana 4
BR - Brasile 3
CL - Cile 3
HK - Hong Kong 3
HU - Ungheria 3
AR - Argentina 2
AT - Austria 2
AU - Australia 2
CH - Svizzera 2
GR - Grecia 2
JP - Giappone 2
NL - Olanda 2
PE - Perù 2
PT - Portogallo 2
SG - Singapore 2
AM - Armenia 1
BD - Bangladesh 1
HR - Croazia 1
IQ - Iraq 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PK - Pakistan 1
PL - Polonia 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 7.401
Salva come PNG Salva come JPEG
Città #
Dublin 731
Fairfield 693
Southend 639
Chandler 319
Jacksonville 308
Ashburn 304
Woodbridge 304
Houston 252
Wilmington 248
Cambridge 240
Seattle 231
Ann Arbor 179
Princeton 140
Beijing 86
Nanjing 80
Siena 76
Helsinki 48
Boardman 45
Nanchang 41
San Diego 41
Dong Ket 36
Shanghai 36
San Mateo 30
Dearborn 27
Shenyang 25
Izmir 24
London 21
Tianjin 21
Málaga 19
Redwood City 19
Hebei 17
Jiaxing 16
Kunming 16
Brussels 15
Venezia 14
Changsha 13
Fremont 12
Norwalk 11
San Francisco 11
New York 10
Düsseldorf 8
Hangzhou 8
Jinan 7
Lancaster 7
Milan 7
Lanzhou 6
Zhengzhou 6
Da Nang 5
Florence 5
Guangzhou 5
Naples 5
Rome 5
Aachen 4
Bonndorf 4
Chiswick 4
Renton 4
Scandicci 4
Sevilla 4
Taizhou 4
Toronto 4
Verrua Po 4
Voghera 4
Washington 4
Zanjan 4
Budapest 3
Chicago 3
Hefei 3
New Bedfont 3
Ningbo 3
Philadelphia 3
Phoenix 3
Villiers-sur-marne 3
Acton 2
Andover 2
Avigliano 2
Bologna 2
Brindisi 2
Campi Bisenzio 2
Dürrenroth 2
Falls Church 2
Fuzhou 2
Greifswald 2
Hong Kong 2
Indiana 2
Islington 2
Kilburn 2
Leonberg 2
Lima 2
Los Angeles 2
Mumbai 2
Paris 2
Ponte Buggianese 2
Pune 2
Reggio Calabria 2
Sant'Agnello 2
Santiago 2
Signa 2
Singapore 2
Tuoro sul Trasimeno 2
Varese 2
Totale 5.600
Salva come PNG Salva come JPEG
Nome #
ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor 160
Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes 159
Endocrine actions of osteocalcin 146
SQSTM1 gene analysis and gene-environment interaction in Paget's disease of bone 144
The usefulness of quantitative ultrasound (QUS) measurements in the evaluation of skeletal status in newborns and in children 139
Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease 137
Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone 133
The association of body composition and sexhormones with quantitative ultrasound parameters at the calcaneus and phalanxes in elderly women. 131
Longitudinal association between sex hormone levels, bone loss and bone turnover in elderly men. 129
Corretto uso dei marcatori del rimodellamento osseo 128
null 128
Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone 125
A non-synonymous TNFRSF11A variation increases NFkB activity and the severity of Paget's disease 125
Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function 124
Prevalence of Paget’s disease of bone in Italy 123
null 122
The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone 121
The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels 119
Aromatase activity and bone loss 119
The influence of weight and length at birth on bone status during childhood as evaluated by QUS 118
Bazedoxifene for the prevention of postmenopausal osteoporosis 117
Quantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in men 115
Aromatase activity and bone loss in men 115
The effects of zoledronic acid on serum lipids in multiple myeloma patients 114
Epidemiological, clinical, and genetic characteristics of Paget's disease of bone in a rural area of Calabria, Southern Italy 114
Mild brachydactyly type A1 maps to chromosome 2q35-q36 and is caused by a novel IHH mutation in a three generation family 112
Paget's disease of bone: epidemiology, pathogenesis and pharmacotherapy 111
Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis 111
Update on the pharmacogenetics of the vitamin D receptor and osteoporosis 110
Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis 110
Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. 109
FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women 107
Perspectives in the treatment and prevention of osteoporosis 106
Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene 105
Mechanisms of impaired bone strength in type 1 and 2 diabetes 105
null 105
Feasibility of quantitative ultrasound measurements on the humerus of newborn infants for the assessment of the skeletal status. 103
Giant cell tumor occurring in familial Paget's disease of bone: report of clinical characteristics and linkage analysis of a large pedigree 103
null 103
Ospemifene use in postmenopausal women 102
Lasofoxifene: Evidence of its therapeutic value in osteoporosis 102
Steroid hormone receptor gene polymorphisms and osteoporosis: a pharmacogenomic review 98
Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis 94
Lasofoxifene: a new-generation SERM for the treatment of postmenopausal osteoporosis 94
Raloxifene in breast cancer prevention 93
Mutation of PFN1 Gene in an Early Onset, Polyostotic Paget-like Disease 92
MANAGEMENT STRATEGIES FOR OSTEOPOROSIS IN THE AGING MALE: FOCUS ON ZOLEDRONIC ACID 89
Bone metabolism in men: role of aromatase activity 87
Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease 86
CALCITRIOLO E OSTEOPOROSI 84
aromatase deficiency and male osteoporosis 81
MicroRNAs in bone diseases 81
Identification of Single Nucleotide Polymorphisms (SNPs) contributing to bone mineral density and fractures: a DNA microarray based study 80
Bone fragility in men: where are we? 73
Vitamin D Status in Paget Disease of Bone and Efficacy-Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D. 73
Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis 73
Hypovitaminosis D and organ damage in patients with arterial hypertension: a multicenter double blind randomised controlled trial of cholecalciferol supplementation (HYPODD) : study design, clinical procedures and treatment protocol 69
Emerging therapeutic targets for osteoporosis 68
Treatment options for glucocorticoid-induced osteoporosis 67
Cortisol secretion, sensitivity, and activity are associated with hypertension in postmenopausal eucortisolemic women 67
Oncogenic osteomalacia 64
Vitamin D deficiency and primary hyperparathyroidism 62
Relationship of sex hormones with bone turnover markers, bone ultrasounds and BMD at multiple sites in men and women 60
la genetica dell'osteoporosi 59
Recent advances in models for screening potential osteoporosis drugs 57
Professional sport activity and micronutrients: effects on bone mass 55
Paget's disease of bone 55
Infection by CagA-Positive Helicobacter pylori Strains and Bone Fragility: A Prospective Cohort Study 52
Interleukin-6 trans-signaling and pathological low back pain in patients with Paget disease of bone 48
Update on the pathogenesis and genetics of Paget's disease of bone 46
Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development 46
The Potential Role of miRNAs as New Biomarkers for Osteoporosis 44
Appropriate models for novel osteoporosis drug discovery and future perspectives 41
Prediction of hypertension, diabetes and fractures in eucortisolemic women by measuring parameters of cortisol milieu 38
Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders 33
Vescicole extracellulari e metabolismo osseo: ruolo e possibili implicazioni cliniche 33
Clinical Characteristics and Evolution of Giant Cell Tumor Occurring in Paget's Disease of Bone 33
Micro-RNA expression profiling in Paget's disease of bone 31
Management of bone fragility in type 2 diabetes:Perspective from an interdisciplinary expert panel 28
Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy 26
Treatment needs and current options for postmenopausal osteoporosis 25
Increased Prevalence of Nephrolithiasis and Hyperoxaluria in Paget Disease of Bone 25
Drug treatment strategies for paget’s disease: relieving pain and preventing progression 24
Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes 22
Role of Advanced Glycation End-Products and Oxidative Stress in Type-2-Diabetes-Induced Bone Fragility and Implications on Fracture Risk Stratification 21
Current options for the treatment of Paget's disease of the bone 17
Paget’s disease of bone: an update on epidemiology, pathogenesis and pharmacotherapy 13
Validation of the clinical consensus recommendations on the management of fracture risk in postmenopausal women with type 2 diabetes 13
Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility 11
Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis 10
Energy metabolism and ketogenic diets: What about the skeletal health? a narrative review and a prospective vision for planning clinical trials on this issue 8
Totale 7.558
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.068
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.068
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019568 0 0 0 0 0 0 0 0 0 106 250 212
2019/20201.781 205 57 108 285 113 132 152 230 158 183 42 116
2020/20211.197 55 142 36 120 41 152 33 230 112 93 96 87
2021/2022862 52 107 41 109 24 25 36 23 47 106 89 203
2022/20231.240 82 91 186 166 120 263 26 95 117 33 40 21
2023/20241.040 123 48 112 46 20 247 396 17 7 24 0 0
Totale 7.558